8-K: Premier Inc. Concludes Strategic Review, Authorizes $1 Billion Share Repurchase Program

Premier Inc. has completed its strategic review, approved a $1 billion share repurchase program, and will seek partners for its Contigo Health and S2S Global businesses.

Summary

• Premier Inc. announced the conclusion of its strategic review process, which began in May 2023.
• The company's board has approved a new $1 billion share repurchase authorization, including a $400 million accelerated share repurchase (ASR) transaction with Bank of America.
• The initial delivery of shares under the ASR is expected by February 9, 2024, with final settlement in the first quarter of fiscal year 2025.
• Premier will seek partners for its Contigo Health and S2S Global businesses to enhance their future success.
• The company reported a 7% decrease in net revenue to $334.7 million for the second quarter of fiscal year 2024, compared to $359.6 million in the prior year.
• Net income decreased by 18% to $52.9 million, and diluted earnings per share decreased by 17% to $0.45.
• Adjusted EBITDA decreased by 18% to $114.1 million, and adjusted EPS decreased by 14% to $0.60.
• The company's fiscal year 2024 guidance includes total net revenue between $1.265 billion and $1.325 billion, adjusted EBITDA between $405 million and $425 million, and adjusted EPS between $2.06 and $2.18.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic review conclusion and share repurchase program are positive, the financial results show significant declines in revenue and profitability. The decision to seek partners for some businesses also introduces uncertainty. Overall, the sentiment is neutral to slightly negative.

Positives

• The conclusion of the strategic review provides clarity on the company's future direction.
• The $1 billion share repurchase authorization signals confidence in the company's prospects and commitment to returning value to stockholders.
• The company is actively seeking partners for non-core assets, which could lead to improved performance and focus.
• Premier has a strong financial position with a flexible balance sheet and no outstanding balance on its $1 billion credit facility.
• The company is seeing growth in its consulting services and adjacent markets businesses, with adjacent markets growing over 29% in aggregate.

Negatives

• Net revenue decreased by 7% in the second quarter of fiscal year 2024.
• Net income and adjusted EBITDA both decreased by 18% in the second quarter of fiscal year 2024.
• The company is experiencing challenges in its direct sourcing business due to excess market supply and inventory levels.
• Performance Services revenue was impacted by a decrease in contributions from enterprise license agreements.
• Free cash flow for the first six months of fiscal year 2024 was an outflow of $63.3 million.

Risks

• The company's ability to complete the ASR transaction and other share repurchases could be affected by volatility or disruptions in the capital markets.
• The company's ability to find suitable partners for Contigo Health and S2S Global is not guaranteed.
• The company's financial performance could be impacted by changes in market conditions, member purchasing, and patient utilization.
• The company's guidance is based on certain assumptions, and actual results may differ.
• The company faces ongoing challenges in the healthcare industry, including labor shortages and supply chain disruptions.

Future Outlook

Premier expects fiscal year 2024 total net revenue to be between $1.265 billion and $1.325 billion, adjusted EBITDA to be between $405 million and $425 million, and adjusted EPS to be between $2.06 and $2.18. The company anticipates free cash flow to be 45% to 55% of adjusted EBITDA, excluding tax payments related to the sale of non-healthcare GPO operations. The company also expects to continue to evaluate opportunities to invest in organic growth and potential acquisitions.

Management Comments

• Michael J. Alkire, Premiers President and CEO, stated that the Board has concluded its review of strategic alternatives and approved a new $1 billion share repurchase authorization.
• Alkire also mentioned that the company will seek partners for its Contigo Health and S2S Global businesses.
• Richard J. Statuto, Chair of the Board, expressed confidence in the company's business, operating strategy, and value-creation opportunities.
• Craig McKasson, Chief Administrative and Financial Officer, noted that the company met its expectations for profitability despite a decline in total net revenue.

Industry Context

The healthcare industry is facing challenges such as labor shortages, supply chain disruptions, and an aging population. Premier is positioning itself as an essential partner by focusing on technology-enabled solutions, AI capabilities, and supply chain efficiencies. The company's strategic review and subsequent actions reflect a broader trend of healthcare companies focusing on core competencies and seeking partnerships to enhance growth.

Comparison to Industry Standards

• Premier's revenue decline of 7% in the second quarter is worse than some of its peers in the healthcare technology and services sector, which have shown more resilience.
• The 18% decrease in adjusted EBITDA is also a significant drop compared to industry averages, indicating potential challenges in cost management and operational efficiency.
• The company's decision to seek partners for Contigo Health and S2S Global is a strategic move that could be compared to other companies divesting non-core assets to focus on their strengths.
• The $1 billion share repurchase program is a positive signal to investors, but its impact will depend on the company's ability to generate sufficient cash flow and maintain a healthy balance sheet.
• Compared to companies like Cardinal Health and McKesson, which are also involved in healthcare supply chain, Premier's direct sourcing business is facing more challenges, indicating a need for strategic adjustments.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and potential value creation from the strategic review.
• Employees may experience changes due to the potential partnerships for Contigo Health and S2S Global.
• Customers will continue to receive services from Premier, with potential enhancements from the partnerships.
• Suppliers may see changes in their relationships with Premier due to the strategic shifts.
• Creditors will be impacted by the company's financial performance and capital allocation decisions.

Next Steps

• The company will implement the $400 million accelerated share repurchase transaction.
• Premier will seek partners for its Contigo Health and S2S Global businesses.
• The company will continue to evaluate opportunities to invest in organic growth and potential acquisitions.
• Premier will provide an update on the remaining $600 million share repurchase authorization in August.

Key Dates

Keywords

share repurchase, strategic review, healthcare, supply chain, GPO, Contigo Health, S2S Global, financial results, EBITDA, accelerated share repurchase, performance services